Catalyst Pharmaceuticals, Inc.

311 articles with Catalyst Pharmaceuticals, Inc.

• Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/15/2021

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29, 2021 through December 2, 2021.

• Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

  11/9/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a corporate update.

• Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST

  10/25/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

• Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

  9/30/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®

• Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/17/2021

  Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences in September 2021

  9/10/2021

  Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate in two upcoming investor conferences:.

• Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

  8/16/2021

  Catalyst Pharmaceuticals, Inc. today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations.

• Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

  7/26/2021

  Catalyst Pharmaceuticals, Inc. today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

• Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

  7/19/2021

  New patent bolsters intellectual property protection for Firdapse® First in a family of four pending patents for Firdapse® to issue

• 

  BioSpace Movers & Shakers, July 9

  7/9/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Movers & Shakers, July 2

  7/2/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

  6/29/2021

  Catalyst Pharmaceuticals, Inc. today announced the appointment of Molly Harper to the Company’s Board of Directors.

• Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

  6/28/2021

  Catalyst Pharmaceuticals, Inc. today announced that it has entered into an exclusive license and supply agreement with DyDo Pharma, Inc. (“DyDo Pharma”) for the development and commercialization of Firdapse.

• Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi

  6/3/2021

  Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada's approval of Medunik's New Drug Submission (NDS) for Ruzurgi®.

• Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

  5/19/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. Chief Scientific Officer /COO, will participate in two upcoming investor conferences:

• Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

• Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

  5/3/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release first quarter 2021 financial results after market close on Monday, May 10, 2021.

• Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

  3/15/2021

  - Firdapse ® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

• Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

  3/4/2021

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year-end 2020 financial results after market close on Monday, March 15, 2021.